Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale) Occluder
Study Details
Study Description
Brief Summary
The purpose of the study is to collect more data about performance and safety of the device called "IrisFITTM PFO occluder". This data will be used to help more patients who will accept treatment with this device in the future.
Patients will undergo routine examination, procedure and follow-up. Related data will be collected and kept in a way that patient info is well protected.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This is a Post Market Clinical Follow-up study. Informed consent will be obtained from the patient or from a legally authorized representative of the patient at screening. The patients will be screened (pre-procedure) to determine eligibility for the study. At screening, patients will be assessed for study eligibility by the inclusion/exclusion criteria through their medical history, demographics and transthoracic echocardiography (TTE). Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device. The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: IrisFIT PFO Occluder Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit. |
Device: IrisFIT PFO Occluder
|
Outcome Measures
Primary Outcome Measures
- Adverse device effects during the procedure up to the point of implanting the study device in the PFO, and during completion of the procedure [during completion of the procedure]
Adverse device effects during the procedure up to the point of implanting the study device in the PFO, and during completion of the procedure
- Device related adverse event up to 1 month follow-up [1 month post procedure]
Device related adverse event up to 1 month follow-up
- Device related adverse event up to 12 month follow-up [12 month post procedure]
Device related adverse event up to 12 month follow-up
- Rate of accurate device placement [6 month post procedure]
Rate of accurate device placement
- Incidence of device migration/malfunction [6 month post procedure]
Incidence of device migration/malfunction
- Successful closure/procedure rate: Proper position of the occluder by imaging, with trivial to small or without residual shunt, 6 month after procedure). [6 month post procedure]
Successful closure/procedure rate: Proper position of the occluder by imaging, with trivial to small or without residual shunt, 6 month after procedure).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients who are according to current international or local guidelines (and future revisions) and per physician discretion scheduled for interventional treatment of PFO.
-
Patients who are willing and capable of providing informed consent and participating in all testing/or follow procedure associated with this study.
-
Patients who are eligible for treatment with IrisFIT PFO occluder device. (Per physician discretion and device IFU).
Exclusion Criteria:
-
PFO tunnel length <1 mm
-
Women of childbearing potential who are or plan to become pregnant during the time of the study (method of assessment upon physician's discretion)
-
Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cardio Vasculäres Centrum Frankfurt | Frankfurt | Germany | ||
| 2 | Helmut-G.-Walther-Klinikum | Lichtenfels | Germany | ||
| 3 | Mater Misericordiae University Hospital | Dublin | Ireland |
Sponsors and Collaborators
- Lifetech Scientific (Shenzhen) Co., Ltd.
Investigators
- Principal Investigator: HORST SIEVERT, CARDIOVÄSCULARES CENTRUM FRANKFURT GERMANY
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PFO-01